Chadwick V S, Schlup M M, Cooper B T, Broom M F
Wellcome Medical Research Institute, University of Otago Medical School, Dunedin, New Zealand.
J Gastroenterol Hepatol. 1990 Jul-Aug;5(4):375-81. doi: 10.1111/j.1440-1746.1990.tb01412.x.
Bacterial chemotactic F-met peptides have been identified in culture supernatants of intestinal bacteria and in human faecal dialysates. These potent inflammatory agents could play a role in intestinal inflammatory disorders should they cross the epithelial barrier of the gut. We have identified mucosal peptidases which degrade F-met-leu-phe (FMLP) in ileal and colonic mucosal biopsies obtained at colonoscopy. A carboxypeptidase, inhibited by D-L-benzyl succinate (BzS), accounted for more than 60% of total FMLP-ase activity, other uncharacterized peptidases contributing the rest of the activity against the intact peptide. An F-met deformylase, inactive against di- and tri-peptides, cleaves released F-met completing the degradation. Total FMLP-ase, carboxypeptidase and F-met deformylase activities were measured in serial mucosal biopsies from 15 control patients undergoing colonoscopy for occult bleeding with negative findings and from 15 patients with ulcerative colitis (UC) and 10 with Crohn's disease (CD). Highest activities were found in terminal ileum and lowest in the rectum. Total FMLP-ase and carboxypeptidase activities were similar in controls and UC patients but were substantially reduced in CD, especially in the terminal ileum (controls 493 +/- 146 and 116 +/- 73 nmol/100 micrograms protein per h, respectively and CD 231 +/- 96 and 41 +/- 36 nmol/100 micrograms protein per h, respectively (P = 0.0018 and 0.015). F-met deformylase activities were similar in all groups. There was no correlation between enzyme activity and severity of inflammation. FMLP degrading peptidases probably contribute to the mucosal barrier of the gut in regions of high bacterial colonization, limiting intestinal absorption and inflammatory responses to these potent bacterial products in the intestinal lumen.
已在肠道细菌的培养上清液和人粪便透析液中鉴定出细菌趋化性F-甲硫氨酸肽。这些强效炎症介质若穿过肠道上皮屏障,可能在肠道炎症性疾病中起作用。我们在结肠镜检查时获取的回肠和结肠黏膜活检组织中鉴定出了可降解F-甲硫氨酰-亮氨酰-苯丙氨酸(FMLP)的黏膜肽酶。一种被D-L-苄基琥珀酸(BzS)抑制的羧肽酶,占总FMLP酶活性的60%以上,其他未鉴定的肽酶对完整肽的活性贡献了其余部分。一种对二肽和三肽无活性的F-甲硫氨酸去甲酰基酶,可裂解释放出的F-甲硫氨酸,从而完成降解过程。对15名因隐匿性出血接受结肠镜检查且结果为阴性的对照患者、15名溃疡性结肠炎(UC)患者和10名克罗恩病(CD)患者的系列黏膜活检组织,测定了总FMLP酶、羧肽酶和F-甲硫氨酸去甲酰基酶的活性。最高活性见于回肠末端,最低活性见于直肠。对照患者和UC患者的总FMLP酶和羧肽酶活性相似,但CD患者的活性显著降低,尤其是在回肠末端(对照患者分别为493±146和116±73 nmol/100μg蛋白质每小时,CD患者分别为231±96和41±36 nmol/100μg蛋白质每小时,P = 0.0018和0.015)。所有组的F-甲硫氨酸去甲酰基酶活性相似。酶活性与炎症严重程度之间无相关性。FMLP降解肽酶可能在细菌高度定植区域对肠道黏膜屏障起作用,限制肠道对这些肠道腔中强效细菌产物的吸收和炎症反应。